New Zealand markets closed

Inovio Pharmaceuticals, Inc. (INO)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
10.37+0.24 (+2.42%)
As of 11:30AM EDT. Market open.
Currency in USD

Valuation measures4

Market cap (intra-day) 262.30M
Enterprise value 147.22M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)269.84
Price/book (mrq)2.24
Enterprise value/revenue 176.95
Enterprise value/EBITDA -1.13

Trading information

Stock price history

Beta (5Y monthly) 1.12
52-week change 39.63%
S&P500 52-week change 321.08%
52-week high 314.75
52-week low 33.84
50-day moving average 310.42
200-day moving average 36.80

Share statistics

Avg vol (3-month) 3479.7k
Avg vol (10-day) 3374.25k
Shares outstanding 525.91M
Implied shares outstanding 625.91M
Float 823.03M
% held by insiders 11.48%
% held by institutions 116.63%
Shares short (15 Apr 2024) 42.26M
Short ratio (15 Apr 2024) 45.55
Short % of float (15 Apr 2024) 49.76%
Short % of shares outstanding (15 Apr 2024) 49.68%
Shares short (prior month 15 Mar 2024) 42.06M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 21:12
Last split date 325 Jan 2024

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin 0.00%
Operating margin (ttm)-26,686.29%

Management effectiveness

Return on assets (ttm)-32.11%
Return on equity (ttm)-79.55%

Income statement

Revenue (ttm)832.01k
Revenue per share (ttm)0.04
Quarterly revenue growth (yoy)-17.70%
Gross profit (ttm)N/A
EBITDA -130.66M
Net income avi to common (ttm)-135.12M
Diluted EPS (ttm)-6.09
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)145.29M
Total cash per share (mrq)6.22
Total debt (mrq)30.21M
Total debt/equity (mrq)25.74%
Current ratio (mrq)3.60
Book value per share (mrq)5.15

Cash flow statement

Operating cash flow (ttm)-124.37M
Levered free cash flow (ttm)-86.15M